Optimized Outcomes.

- Acquired By -

Falcon Capital Partners Advises PharmaMetrics in its sale to IntegriChain

WAYNE, PENNSYLVANIA – July 1, 2017 : Falcon Capital Partners, LLC, a leading middle-market investment bank, announced today the successful sale of PharmaMetrics to IntegriChain.

PharmaMetrics, headquartered in nearby Fort Washington, PA, is a leading provider of contract operations outsourcing and market access analytics software and services for the pharmaceutical industry. Philadelphia-based IntegriChain is a rapidly growing healthcare technology company and this acquisition strengthens their ability to deliver industry-leading analytics and contract management solutions to pharmaceutical managed markets teams to support their growing investments in patient access. This is IntegriChain’s first acquisition since entering its strategic partnership with Accel-KKR, a leading technology-focused private equity firm, in 2016.

“We are excited to join the growing IntegriChain platform to enhance the delivery of contracting and payer analytics to today’s leading and emerging managed market teams,” said John Still, President and CEO of PharmaMetrics. “Our offerings are highly complementary – combining the worlds of payer and payer rebates with specialty patient-level, pharmacy, and distribution data – and will improve market access and patient experience optimization in the specialty era.”

The terms of the transaction were not disclosed.

The Falcon deal team was led by Managing Director Ted Stack and Senior Associate Don Wanner. For more information please contact Ted Stack, Managing Director at 610-989-8901 or Don Wanner, Senior Associate at 610-989-8907.

Click Here For IntegriChain’s Full Press Release

A One-page Summary of Our Firm